Circio Holding ASA (”Circio” or ”the Company”) announced, on the 15th of May 2026, the publication of an extensive new circVec-AAV data package presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Boston, 11–15 May 2026. The materials comprise a poster presentation on 13 May detailing in vivo cardiac findings and an oral presentation by CEO Dr. Erik D. Wiklund on 15 May providing a platform-level overview.
Analyst Group’s View on the New Data Points
A New Safety Differentiator Emerges
The headline expression multiples (approx. 40x in heart, approx. 50x in eye) had already been disclosed earlier in 2026. Among the analytically meaningful additions is more detailed characterization of cellular stress. When cells are forced to produce large amounts of foreign protein, as is the case in AAV gene therapy, they activate the unfolded protein response (UPR), a stress pathway widely recognized as a major contributor to AAV-related toxicity and the serious adverse events that have historically constrained clinical advancement. Intuitively, more expression should mean more stress. The expanded ASGCT data shows the opposite: circVec-AAV reduces UPR activation relative to conventional AAVs, both in heart tissue and in supporting cell-line testing, despite producing approx. 40x more protein. Analyst Group considers this an important differentiator that suggests circVec could enable higher efficacy and improved safety simultaneously, directly addressing the dose-toxicity trade-off that constrains AAV gene therapy today.
Heart Dataset Extended with Stronger Construct and Broader Cellular Coverage
The ASGCT package also extends the heart dataset in two ways. First, the next-generation circVec 4.0 construct, previously highlighted primarily in the eye context, is shown to deliver an approx. 50% additional improvement over the prior circVec 3.2 baseline in heart. Second, approx. 80% of cardiomyocytes are shown to express circRNA at a low dose level, meaning that the advantage is distributed broadly across heart tissue rather than concentrated in a small number of cells, a characteristic important for therapeutic efficacy in genetic cardiomyopathy indications such as Danon disease. In parallel, the heart-specific dose-response analysis now characterizes circVec performance at the RNA transcript level across the tested dose range, demonstrating both the number of transcripts produced per cell and the percentage of heart cells transduced at each dose level. This provides a more granular mechanistic understanding of how circVec maintains strong expression at substantially lower doses than conventional AAVs, and supports an opportunity for at least 10–20x dose reduction relative to the doses currently used in clinical AAV programs. Lower doses translate directly into improved safety margins, reduced manufacturing complexity, and lower cost of goods, three factors that frequently constrain AAV gene therapy from reaching commercial viability. Extending the dose-sparing observation from eye to heart confirms it as a generalizable platform property rather than a tissue-specific effect.
Strategic Visibility in a Key Partnering Forum
Beyond the scientific content, the ASGCT annual meeting functions as one of the most concentrated venues globally for pharmaceutical and biotechnology business development teams to engage with emerging gene and cell therapy platforms. Analyst Group considers Circio’s selection for an oral presentation, in addition to the poster, well-timed: it falls between the strengthened cross-tissue data package disclosed earlier in 2026 and the upcoming disease-model efficacy readouts in H2-26, providing a direct opportunity to deepen dialogues with existing partners and to engage prospective licensees ahead of those events. The relevance is reinforced by the recent transaction backdrop, where preclinical-stage RNA and expression-enhancing platforms have attracted substantial capital, including BMS/Orbital (USD 1.5bn) and Eli Lilly/Orna (USD 2.4bn).
In summary, Analyst Group views the ASGCT data package as analytically more meaningful than a repetition of previously announced expression multiples. The expanded UPR/cellular stress data reinforces circVec’s safety profile, while the stronger heart performance with circVec 4.0, the broad cellular coverage at low dose, and the heart-specific dose-sparing curve, now substantiated at the RNA transcript level, reinforce the basis for the H2-26 disease-model readouts. Combined with the visibility provided by the ASGCT forum itself, the package strengthens both the scientific foundation and the partnering momentum of the licensing narrative.
About ASGCT
The American Society of Gene & Cell Therapy (ASGCT) is the primary professional organization for researchers and developers within gene and cell therapy. Its annual meeting is widely regarded as the largest and most prestigious scientific conference in the field globally, bringing together academic researchers, pharmaceutical and biotechnology companies, regulatory representatives, patient advocacy groups, and life science media, and serving as a key venue where companies and potential partners convene around licensing and collaborative R&D opportunities.
